Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Jul 30;12:6083–6092. doi: 10.2147/OTT.S211560

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 Liang et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

The inhibition of ATR reverses cisplatin-induced inhibition of cell proliferation. (A) CCK-8 analysis of the proliferation of SW1353 and CS-1 cells treated with the indicated concentrations of VE-822 for 24 h. (B) CCK-8 analysis of the proliferation of SW1353 and CS-1 cells treated with the indicated concentrations of VE-822 and cisplatin for 24 h. (C) CCK-8 analysis of the proliferation of SW1353 cells that were untreated or treated with VE-822 (0.2 μM, 48 h), cisplatin (20 μM, 48 h), VE-822 (0.2 μM, 48 h) + cisplatin (20 μM, 24 h), or cisplatin (20 μM, 48 h) + VE-822 (0.2 μM, 24 h). (D) CCK-8 analysis of the proliferation of SW1353 cells that were untreated or treated with cisplatin (10 μM, 48 h) or cisplatin (10 μM, 48 h) plus VE-822 (0.05 μM, 48 h) and of SW1353 cells transfected with empty vector (E.V.) and treated with cisplatin (10 μM, 48 h) or transfected with ATR shRNA and treated with cisplatin (10 μM, 48 h). *P<0.05, **P<0.01, ***P<0.001.